AAD: Zasocitinib Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Adults

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, April 3, 2026 -- Once-daily oral zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, provides a durable response in adults with moderate-to-severe plaque psoriasis (PsO), according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Melinda Gooderham, M.D., from the SKiN Centre for Dermatology in Peterborough, Ontario, Canada, and colleagues led the Latitude PsO 3001 and 3002 phase 3 studies in which zasocitinib (30 mg once daily) was compared to placebo or apremilast (30 mg twice daily) over 52 (LATITUDE-PsO-3001; 693 patients) or 60 weeks (LATITUDE-PsO-3002; 1,108 patients).

The researchers found that at week 16, in both trials, zasocitinib met co-primary end points versus placebo (static Physician Global Assessment [sPGA 0/1]: zasocitinib, 71.4 and 69.2 percent; placebo, 10.7 and 12.6 percent; Psoriasis Area and Severity Index 75 [PASI75]: zasocitinib, 75.7 and 71.4 percent; placebo 12.1 and 12.3 percent). In both trials, zasocitinib also demonstrated superiority over apremilast (sPGA 0/1: apremilast, 32.1 and 29.7 percent; PASI75: apremilast, 37.2 and 33.0 percent). Improvement was seen through week 24. PASI75 superiority was seen as early as week 4 in LATITUDE-PsO-3002 (PASI75: zasocitinib, 16.8 percent; placebo 4.3 percent). At week 24, superiority of zasocitinib over apremilast was seen for PASI90 and PASI100 (PASI90: zasocitinib, 69.0 and 62.7 percent; apremilast, 20.4 and 17.0 percent; PASI100: zasocitinib, 42.3 and 32.1 percent; apremilast 5.1 and 3.3 percent). Laboratory and safety parameters were consistent with previous studies. The most frequent adverse events (≥5 percent) occurring with zasocitinib were upper respiratory tract infection, nasopharyngitis, and acne.

"Our phase 3 results demonstrate that highly selective TYK2 inhibition can offer many people with moderate-to-severe plaque psoriasis the potential for clear or nearly clear skin," Chinwe Ukomadu, M.D., Ph.D., from Takeda Pharmaceuticals, said in a statement. "The positive data also underscore zasocitinib's potential to deliver rapid and durable results with a favorable safety profile consistent with phase 2b studies."

The study was funded by Takeda, the manufacturer of zasocitinib.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-04 08:52

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords